Sublocade clinical trials
A product of Buprenorphine; its studies count on that page too.
How each study uses Sublocade is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Sublocade studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 30 Nov 2017 · SUBLOCADE · NDA 209819 (FDA, Drugs@FDA)
- European Union
- 26 Sept 2006 · Suboxone · EMEA/H/C/000697 (EMA; as Buprenorphine; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2019 (4)
| Year | Studies |
|---|---|
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 13
Indivior Inc. (3) · NYU Langone Health (2) · Virginia Commonwealth University (2) · Gavin Bart (1) · Friends Research Institute, Inc. (1) · Frances R Levin (1) · University of Texas Southwestern Medical Center (1) · New York State Psychiatric Institute (1)
Often tested with
Tested in the same studies.
INDV-6001 (1) · Naltrexone (1) · Cabotegravir, rilpivirine drug combination (1)
Related medicines
As reviewed, each with the page that says it.
- A brand or code of Buprenorphine
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Sublocade.
- Dec 2026Assessing Optimal XRB Initiation Points in JailPhase 4 · NYU Langone Health
- Jan 2027Injectable Buprenorphine in Prison: A Preference TrialPhase 4 · Lifespan
Studies
Open first, then newest update. How each study uses Sublocade is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- Assessing Optimal XRB Initiation Points in JailRecruitingPhase 4NYU Langone HealthNCT06051890Written as Extended-Release Buprenorphine (XRB)
- Injectable Buprenorphine in Prison: A Preference TrialRecruitingPhase 4LifespanNCT06880718Written as Sublocade
- EXHIT ENTRE Comparative Effectiveness TrialCompletedPhase 2/3Gavin BartNCT04345718Written as Extended Release Buprenorphine
- Telemedicine XR-B for Individuals in JailCompletedPhase 3Friends Research Institute, Inc.NCT07524738Written as Extended Release Buprenorphine
- Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use DisorderCompletedPhase 2Frances R LevinNCT04352166Written as extended-release buprenorphine (BXR)
- INDV-6001 Multiple-Dose Pharmacokinetic StudyCompletedPhase 2Indivior Inc.NCT06576843Written as Sublocade
- Combined Injectable Treatment for HIV and OUDWithdrawnPhase 2Rhode Island HospitalNCT05991622Written as Combined LAI Treatment: Cabenuva and Sublocade
- Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)CompletedPhase 2University of Texas Southwestern Medical CenterNCT05262270Written as Extended Release Buprenorphine
- SUBLOCADE Rapid Initiation StudyCompletedPhase 4Indivior Inc.NCT03993392Written as SUBLOCADE
- SUBLOCADE Rapid Initiation Extension StudyCompletedPhase 4Indivior Inc.NCT04060654Written as Sublocade
- Assessing Optimal XR-Buprenorphine Initiation Points in JailWithdrawnPhase 4NYU Langone HealthNCT05481112Written as Extended-Release Buprenorphine Injection
- Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use DisorderStatus unknownPhase 4Royal Victoria Hospital, CanadaNCT05594121Written as Extended Release Subcutaneous Buprenorphine
- Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone FilmsWithdrawnPhase 2Wake Forest University Health SciencesNCT03744663Written as Sublocade®
- Virginia Opioid Overdose Treatment InitiatVETerminatedPhase 3Virginia Commonwealth UniversityNCT03818399Written as SUBLOCADE
- An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use DisorderCompletedPhase 1/2New York State Psychiatric InstituteNCT03861338Written as Sublocade
- Virginia Opioid Treatment-Emergency DepartmentWithdrawnPhase 3Virginia Commonwealth UniversityNCT04523792Written as SUBLOCADE